Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kissei Of Japan Licenses Diabetes Drug Rights To GSK

This article was originally published in PharmAsia News

Executive Summary

Kissei Pharmaceutical announced June 2 that it signed an agreement with GlaxoSmithKline and granted GSK exclusive development and sales rights to its type 2 diabetes treatment compounds KGT, a group of selective SGLT-2 inhibitors developed by Kissei. The agreement, along with a previous one signed in 2002, grants GSK worldwide rights, including Japan. KGT is at the end of Phase II trials overseas, and it completed Phase I trials in Japan. Focusing on diabetes drug development, Kissei developed Glufast (mitiglinide) and jointly marketed it with Takeda Pharmaceutical in 2004. The GSK agreement will allow Kissei to focus on Glufast's marketing. (Click here for more - Japanese language

You may also be interested in...

IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher

New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.

Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts